Recent statutory changes have opened the door for a modest increase in qui tam actions over the last several years, a development that coincides with an increase in big-dollar recoveries.
Last November, Zane Memeger, U.S. attorney for the Eastern District of Pennsylvania, announced a record settlement for a single drug, the antipsychotic Risperdal, that was part of a $2.2 billion global accord with subsidiaries of Johnson & Johnson.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
